Eli Lilly to Collaborate with Open AI to Tackle Antimicrobial Resistance
Antimicrobial resistance (AMR) is currently one of the greatest threats to public health globally. Eli Lilly (NYSE: LLY)has announced that it will collaborate with the artificial intelligence research company, OpenAI, to use generative AI to invent novel antimicrobials to treat drug-resistant pathogens.
Diogo Rau, executive vice president and chief information and digital officer at Lilly, said in a statement, “Our collaboration with OpenAI represents a groundbreaking step forward in the fight against the growing but overlooked threat of antimicrobial resistance.
“Generative AI opens a new opportunity to accelerate the discovery of novel antimicrobials and the development of custom, purpose-built technologies in the battle against drug-resistant pathogens. This partnership underscores our commitment to addressing significant health challenges experienced by people around the world.”
Antimicrobial resistance affects countries in all regions and at all income levels. Overuse of antimicrobials in humans, animals and plants are the main drivers in the development of drug-resistant pathogens. Antibiotics are a type of antimicrobial, but not all antimicrobials are antibiotics. Antimicrobials act on bacteria, viruses, fungi, and parasites.
About Lilly
Lilly is a medicine company turning science into healing to make life better for people around the world. We’ve been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 51 million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world’s most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer’s disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we’re motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable.
